BioStock: FDA CAR T investigation does not affect Elicera

The FDA is investigating safety risks in patients receiving CAR T-cell immunotherapies after reports of T-cell malignancies, including CAR-positive lymphoma. All six approved CAR T drugs are being placed under increased scrutiny by the American regulators. We spoke with Jamal El-Mosleh, CEO of cell- and gene therapy company Elicera Therapeutics, to see how this might affect a CAR T developer like Elicera.

Read the interview with Jamal El-Mosleh at biostock.se:

FDA CAR T investigation does not affect Elicera - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/